Compare Novavax Inc (NVAX) vs Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Direxion NASDAQ 100 Equal Weighted Index Shares — how do they compare? Novavax Inc trades at $9.9 (market cap $1.68B), while Direxion NASDAQ 100 Equal Weighted Index Shares trades at $118.73. Which is the better fit depends on your goals.
| NVAX | QQQE | |
|---|---|---|
Market Cap | $1.68B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $11.19 | $124.69 |
52-Week Low | $6.22 | $96.06 |
Enterprise Value | $1.26B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $10.19, down 0.29% today, with a bullish technical signal from moving averages but overbought RSI levels. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook. Key developments include regulatory approvals for its updated COVID-19 vaccine in the U.S., EU, and Japan for the 2026-2027 season, alongside ongoing partnerships with Sanofi and Pfizer.
The outlook is mixed: strong analyst buy ratings (73.9%) and partnership milestones offer upside, but negative net income margins and cash flow challenges pose risks. Investors should weigh the potential from vaccine demand and adjuvant platform royalties against financial sustainability concerns and competitive pressures in the biotech sector.
QQQE trades at $119.78, down 0.8% on the day, with a neutral technical signal overall. The ETF provides equal-weighted exposure to the Nasdaq-100, reducing concentration risk compared to market-cap weighted alternatives. Recent news highlights the potential inclusion of SpaceX in the underlying index, which could drive new investor interest. Technical indicators show mixed signals with bullish moving averages but neutral oscillators.
The outlook for QQQE remains tied to Nasdaq-100 performance, with equal weighting offering defensive characteristics during market rotations. Key risks include tech sector volatility and index composition changes. The ETF's structure provides diversification benefits for investors seeking Nasdaq exposure without heavy concentration in mega-cap tech names.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Direxion NASDAQ 100 Equal Weighted Index Shares
QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Read more on QQQE →
